Windtree Therapeutics
Updated: December 24, 2025
Craig Fraser - CEO
Country: USA | Funding: $733.3M (+)
Founded: 1992
Website: https://www.windtreetx.com/
Windtree Therapeutics develops cardiovascular drugs. Its flagship drug Istaroxime is a first-in-class, dual-mode therapy designed to improve cardiac function by increasing both systolic contractility and diastolic relaxation through SERCA2a activation and Na+/K+ ATPase inhibition. The company's heart failure portfolio also includes sarcoendoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) activators, which activate SERCA2a. These candidates will be developed as potential oral treatments for chronic heart failure.
Founded: 1992
Website: https://www.windtreetx.com/
Windtree Therapeutics develops cardiovascular drugs. Its flagship drug Istaroxime is a first-in-class, dual-mode therapy designed to improve cardiac function by increasing both systolic contractility and diastolic relaxation through SERCA2a activation and Na+/K+ ATPase inhibition. The company's heart failure portfolio also includes sarcoendoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) activators, which activate SERCA2a. These candidates will be developed as potential oral treatments for chronic heart failure.
